跳至主要内容
临床试验/NCT00650468
NCT00650468已完成4 期

A Prospective, Randomized, Multi-Center Double-Blind Study of Early Corticosteroid Cessation vs. Long Term Corticosteroid Therapy With Prograf and CellCept in Primary Renal Transplant Patients

Astellas Pharma Inc0 个研究点目标入组 397 人开始时间: 1999年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
397
主要终点
Assessment of death, graft loss, or severe acute rejection

研究概览

简要总结

A study comparing the early withdrawal of steroids to long-term maintenance steroid therapy in Kidney Transplant Patients receiving Prograf and Cellcept

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

1

Experimental

early steroid cessation

干预措施: tacrolimus (Drug)

1

Experimental

early steroid cessation

干预措施: CellCept (Drug)

1

Experimental

early steroid cessation

干预措施: steroids (methylprednisone or prednisone) (Drug)

2

Experimental

long-term maintenance steroids

干预措施: tacrolimus (Drug)

2

Experimental

long-term maintenance steroids

干预措施: CellCept (Drug)

2

Experimental

long-term maintenance steroids

干预措施: steroids (methylprednisone or prednisone) (Drug)

结局指标

主要结局

Assessment of death, graft loss, or severe acute rejection

时间窗: 6 months, 12 months, yearly up to 5 years

次要结局

  • Comparison of patient and graf survival(6 months, 12 months, yearly up to 5 years)
  • Incidence and severity of acute rejection(6 months, 12 months, yearly up to 5 years)
  • Need for antilymphocyte treatment(6 months, 12 months, yearly up to 5 years)
  • Graft function(6 month, 12 months, yearly up to 5 years)
  • Framingham Coronary Heart Disease Risk Factors(6 months, 12 months, yearly up to 5 years)

研究者

申办方类型
Industry

相似试验